Serum metabolic profiles in overweight and obese women with and without metabolic syndrome

Diabetology & Metabolic Syndrome

Sulin Cheng³  Markku Alen¹  Urho M Kujala³  ShuMei Cheng³  Juha Saltevo²  Leiting Xu⁴  Eveliina Munukka³  Reija Autio⁵  Satu Pekkala³  Petri K Wiklund⁶ 

[1] Institute of Health Sciences, University of Oulu, Oulu, Finland;Central Hospital Central Finland, Jyväskylä, Finland;Department of Health Sciences, University of Jyväskylä, Jyväskylä FIN-40014, Finland;Ningbo University School of Medicine, Ningbo, China;Department of Signal Processing, Tampere University of Technology, Tampere, Finland;Department of Medical Rehabilitation, Oulu University Hospital, Oulu, Finland

关键词: Women;    Metabolomics;    Metabolic syndrome;    Obesity;   

Others  :  804965
DOI  :  10.1186/1758-5996-6-40

 received in 2014-03-05, accepted in 2014-03-11,  发布年份 2014

【 摘 要 】

Objective

To identify serum biomarkers through metabolomics approach that distinguishes physically inactive overweight/obese women with metabolic syndrome from those who are metabolically healthy, independent of body weight and fat mass.

Methods

We applied nuclear magnetic resonance spectroscopy-based profiling of fasting serum samples to examine the metabolic differences between 78 previously physically inactive, body weight and fat mass matched overweight/obese premenopausal women with and without MetS. MetS was defined as the presence of at least three of the following five criteria: waist circumference ≥88 cm, serum triacylglycerol ≥1.7 mmol/L, and high density lipoprotein cholesterol (HDL-C) <1.30 mmol/L, blood pressure ≥ 130/85 mmHg and fasting glucose ≥5.6 mmol/L). Principal component analysis was used to reduce the large number of correlated variables to fewer uncorrelated factors.

Results

Two metabolic factors were associated with MetS independent of BMI, fat mass, waist circumference and physical activity/fitness. Factor comprising branched-chain amino acids (BCAA) and aromatic amino acids (AAA) and orosomucoid was associated with all clinical risk factors (p < 0.01 for all).

Conclusion

Two metabolic factors distinguish overweight/obese women with metabolic syndrome from those who are metabolically healthy independent of body weight, fat mass and physical activity/fitness. In particular, factor comprising BCAA, AAA and orosomucoid seems auspicious biomarker determining metabolic health as it was associated with all clinical risk factors. Further research is needed to determine the public health and clinical significance of these results in terms of screening to identify those at greatest cardio-metabolic risk for whom appropriate intervention strategies should be developed.

【 授权许可】

   
2014 Wiklund et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American heart association/national heart, lung, and blood institute scientific statement. Curr Opin Cardiol 2006, 21(1):1-6.
• [2]Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the third national health and nutrition examination survey, 1988–1994. Arch Intern Med 2003, 163(4):427-436.
• [3]Muoio DM, Newgard CB: Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9(3):193-205.
• [4]Rasouli N, Molavi B, Elbein SC, Kern PA: Ectopic fat accumulation and metabolic syndrome. Diabetes Obes Metab 2007, 9(1):1-10.
• [5]Munukka E, Wiklund P, Pekkala S, Volgyi E, Xu L, Cheng S, Lyytikainen A, Marjomaki V, Alen M, Vaahtovuo J, Keinänen-Kiukaanniemi S, Cheng S: Women with and without metabolic disorder differ in their gut microbiota composition. Obesity (Silver Spring) 2012, 20(5):1082-1087.
• [6]Guilherme A, Virbasius JV, Puri V, Czech MP: Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008, 9(5):367-377.
• [7]Abete I, Astrup A, Martinez JA, Thorsdottir I, Zulet MA: Obesity and the metabolic syndrome: role of different dietary macronutrient distribution patterns and specific nutritional components on weight loss and maintenance. Nutr Rev 2010, 68(4):214-231.
• [8]Gill JM, Malkova D: Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity. Clin Sci (Lond) 2006, 110(4):409-425.
• [9]Kujala UM, Jokelainen J, Oksa H, Saaristo T, Rautio N, Moilanen L, Korpi-Hyovalti E, Saltevo J, Vanhala M, Niskanen L, Peltonen M, Tuomilehto J, Uusitupa M, Keinänen-Kiukaannemi S: Increase in physical activity and cardiometabolic risk profile change during lifestyle intervention in primary healthcare: 1-year follow-up study among individuals at high risk for type 2 diabetes. BMJ Open 2011, 1(2):e000292.
• [10]Pajunen P, Kotronen A, Korpi-Hyovalti E, Keinanen-Kiukaanniemi S, Oksa H, Niskanen L, Saaristo T, Saltevo JT, Sundvall J, Vanhala M, Uusitupa M, Peltonen M: Metabolically healthy and unhealthy obesity phenotypes in the general population: the FIN-D2D survey. BMC Public Health 2011, 11:754. BioMed Central Full Text
• [11]Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET: Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004, 89(6):2569-2575.
• [12]Bluher M: The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol 2010, 21(1):38-43.
• [13]Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009, 120(16):1640-1645.
• [14]Lyytikainen A, Lamberg-Allardt C, Kannas L, Cheng S: Food consumption and nutrient intakes with a special focus on milk product consumption in early pubertal girls in central Finland. Public Health Nutr 2005, 8(3):284-289.
• [15]Volgyi E, Lyytikainen A, Tylavsky FA, Nicholson PH, Suominen H, Alen M, Cheng S: Long-term leisure-time physical activity has a positive effect on bone mass gain in girls. J Bone Miner Res 2010, 25(5):1034-1041.
• [16]Weir JB: New methods for calculating metabolic rate with special reference to protein metabolism: 1949. Nutrition 1990, 6(3):213-221.
• [17]Inouye M, Kettunen J, Soininen P, Silander K, Ripatti S, Kumpula LS, Hamalainen E, Jousilahti P, Kangas AJ, Männisto S, Savolainen MJ, Jula M, Leiviskä J, Palotie A, Salomaa V, Perola M, Ala-Korpela M, Peltonen L: Metabonomic, transcriptomic, and genomic variation of a population cohort. Mol Syst Biol 2010, 6:441.
• [18]Soininen P, Kangas AJ, Wurtz P, Tukiainen T, Tynkkynen T, Laatikainen R, Jarvelin MR, Kahonen M, Lehtimaki T, Viikari J, Raitakari OT, Savolainen MJ, Alakorpela M: High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 2009, 134(9):1781-1785.
• [19]Kettunen J, Tukiainen T, Sarin AP, Ortega-Alonso A, Tikkanen E, Lyytikainen LP, Kangas AJ, Soininen P, Wurtz P, Silander K, Dick DM, Rose RJ, Savolainen MJ, Viikari J, Kähönen M, Lehtimäki T, Pietiläinen KH, Inouye M, McCarthy MI, Jula M, Eriksson J, Raitakari OT, Salomaa V, Kaprio J, Järvelin MR, Peltonen L, Perola M, Freimer NB, Ala-korpela M, Palotie A, et al.: Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat Genet 2012, 44(3):269-276.
• [20]Stancakova A, Paananen J, Soininen P, Kangas AJ, Bonnycastle LL, Morken MA, Collins FS, Jackson AU, Boehnke ML, Kuusisto J, Ala-korpela M, Kuusisto M: Effects of 34 risk loci for type 2 diabetes or hyperglycemia on lipoprotein subclasses and their composition in 6,580 nondiabetic Finnish men. Diabetes 2011, 60(5):1608-1616.
• [21]Makinen VP, Forsblom C, Thorn LM, Waden J, Kaski K, Ala-Korpela M, Groop PH: Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (the FinnDiane study). Cardiovasc Diabetol 2009, 8:54. BioMed Central Full Text
• [22]Despres JP, Lemieux I, Bergeron J, Pibarot P, Mathieu P, Larose E, Rodes-Cabau J, Bertrand OF, Poirier P: Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28(6):1039-1049.
• [23]Primeau V, Coderre L, Karelis AD, Brochu M, Lavoie ME, Messier V, Sladek R, Rabasa-Lhoret R: Characterizing the profile of obese patients who are metabolically healthy. Int J Obes (Lond) 2011, 35(7):971-981.
• [24]Ordovas JM: Genetic links between diabetes mellitus and coronary atherosclerosis. Curr Atheroscler Rep 2007, 9(3):204-210.
• [25]Chrousos GP: The role of stress and the hypothalamic-pituitary-adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes. Int J Obes Relat Metab Disord 2000, 24(Suppl 2):S50-S55.
• [26]Matsuzawa Y: The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580(12):2917-2921.
• [27]Lasselin J, Capuron L: Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms. Neuroimmunomodulation 2014, 21(2–3):95-101.
• [28]Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004, 114(12):1752-1761.
• [29]Lakshmy R: Metabolic syndrome: role of maternal undernutrition and fetal programming. Rev Endocr Metab Disord 2013, 14(3):229-240.
• [30]Batch BC, Shah SH, Newgard CB, Turer CB, Haynes C, Bain JR, Muehlbauer M, Patel MJ, Stevens RD, Appel LJ, Newby LK, Svetkey LP: Branched chain amino acids are novel biomarkers for discrimination of metabolic wellness. Metabolism 2013, 62(7):961-969.
• [31]Lackey DE, Lynch CJ, Olson KC, Mostaedi R, Ali M, Smith WH, Karpe F, Humphreys S, Bedinger DH, Dunn TN, Thomas AP, Oort PJ, Kieffer DA, Amin R, Bettaieb A, Haj FG, Permana P, Anthony TG, Adams SH: Regulation of adipose branched-chain amino acid catabolism enzyme expression and cross-adipose amino acid flux in human obesity. Am J Physiol Endocrinol Metab 2013, 304(11):E1175-E1187.
• [32]Felig P, Marliss E, Cahill GF Jr: Plasma amino acid levels and insulin secretion in obesity. N Engl J Med 1969, 281(15):811-816.
• [33]Huffman KM, Shah SH, Stevens RD, Bain JR, Muehlbauer M, Slentz CA, Tanner CJ, Kuchibhatla M, Houmard JA, Newgard CB, Kraus WE: Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009, 32(9):1678-1683.
• [34]Tai ES, Tan ML, Stevens RD, Low YL, Muehlbauer MJ, Goh DL, Ilkayeva OR, Wenner BR, Bain JR, Lee JJ, Lim SC, Khoo CM, Shah SH, Newgard CB: Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 2010, 53(4):757-767.
• [35]Higuchi N, Kato M, Miyazaki M, Tanaka M, Kohjima M, Ito T, Nakamuta M, Enjoji M, Kotoh K, Takayanagi R: Potential role of branched-chain amino acids in glucose metabolism through the accelerated induction of the glucose-sensing apparatus in the liver. J Cell Biochem 2011, 112(1):30-38.
• [36]Razavizade M, Jamali R, Arj A, Talari H: Serum parameters predict the severity of ultrasonographic findings in non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int 2012, 11(5):513-520.
• [37]Kotronen A, Yki-Jarvinen H, Sevastianova K, Bergholm R, Hakkarainen A, Pietilainen KH, Juurinen L, Lundbom N, Sorensen TI: Comparison of the relative contributions of intra-abdominal and liver fat to components of the metabolic syndrome. Obesity (Silver Spring) 2011, 19(1):23-28.
• [38]Fournier T, Medjoubi NN, Porquet D: Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000, 1482(1–2):157-171.
• [39]Lee YS, Choi JW, Hwang I, Lee JW, Lee JH, Kim AY, Huh JY, Koh YJ, Koh GY, Son HJ, Masuzaki H, Hotta K, Alfadda AA, Kim JB: Adipocytokine orosomucoid integrates inflammatory and metabolic signals to preserve energy homeostasis by resolving immoderate inflammation. J Biol Chem 2010, 285(29):22174-22185.
• [40]Lin Y, Berg AH, Iyengar P, Lam TK, Giacca A, Combs TP, Rajala MW, Du X, Rollman B, Li W, Hawkins M, Barzilai N, Rhodes CJ, Fantus IG, Brownlee M, Scherer PE: The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005, 280(6):4617-4626.
• [41]Nguyen MT, Satoh H, Favelyukis S, Babendure JL, Imamura T, Sbodio JI, Zalevsky J, Dahiyat BI, Chi NW, Olefsky JM: JNK and tumor necrosis factor-alpha mediate free fatty acid-induced insulin resistance in 3 T3-L1 adipocytes. J Biol Chem 2005, 280(42):35361-35371.
• [42]Kujala UM, Makinen VP, Heinonen I, Soininen P, Kangas AJ, Leskinen TH, Rahkila P, Wurtz P, Kovanen V, Cheng S, Sipilä S, Hirvensalo M, Telama R, Tammelin T, Savolainen MJ, Pouta A, O’Reilly PF, Mäntyselkä P, Viikari J, Kähönen M, Lehtimäki T, Elliott P, Vanhala MJ, Raitakari OT, Järvelin MR, Kaprio J, Kainulainen H, Ala-Korpela M: Long-term leisure-time physical activity and serum metabolome. Circulation 2013, 127(3):340-348.
• [43]Leskinen T, Rinnankoski-Tuikka R, Rintala M, Seppanen-Laakso T, Pollanen E, Alen M, Sipila S, Kaprio J, Kovanen V, Rahkila P, Oresic M, Kainulainen H, Kujala UM: Differences in muscle and adipose tissue gene expression and cardio-metabolic risk factors in the members of physical activity discordant twin pairs. PLoS One 2010, 5(9):e12609.
• [44]Kivela R, Silvennoinen M, Lehti M, Rinnankoski-Tuikka R, Purhonen T, Ketola T, Pullinen K, Vuento M, Mutanen N, Sartor MA, Reunanen H, Koch LG, Britton SL, Kainulainen H: Gene expression centroids that link with low intrinsic aerobic exercise capacity and complex disease risk. FASEB J 2010, 24(11):4565-4574.
• [45]Kahn R, Buse J, Ferrannini E, Stern M: The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2005, 48(9):1684-1699.
• [46]Hosker JP, Matthews DR, Rudenski AS, Burnett MA, Darling P, Bown EG, Turner RC: Continuous infusion of glucose with model assessment: measurement of insulin resistance and beta-cell function in man. Diabetologia 1985, 28(7):401-411.